Page 23 - Aduhelm News Today

Biogen Inc noted delayed uptake of its Alzheimer’s drug, Aduhelm, in the US, but said it continues to believe in the treatment’s long-term potential.

Biogen’s sales for its new Alzheimer’s drug fell short of Wall Street expectations, with the drugmaker reporting on Wednesday that it brought in millions less than anticipated from aduhelm in the third quarter.

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first...

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first...

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first...

The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout...

What can we learn from the FDA’s controversial approval of aducanumab, the Alzheimer’s drug that failed its clinical trials?

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough...

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout...